Kidder Stephen W Purchases 14,635 Shares of Novo Nordisk A/S (NYSE:NVO)

Kidder Stephen W raised its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 576.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,175 shares of the company's stock after purchasing an additional 14,635 shares during the quarter. Kidder Stephen W's holdings in Novo Nordisk A/S were worth $1,193,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of NVO. BIP Wealth LLC grew its stake in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock valued at $313,000 after buying an additional 138 shares during the last quarter. Xponance Inc. grew its stake in shares of Novo Nordisk A/S by 4.9% in the fourth quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after purchasing an additional 146 shares during the last quarter. 180 Wealth Advisors LLC grew its stake in shares of Novo Nordisk A/S by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock worth $348,000 after purchasing an additional 173 shares during the last quarter. LRI Investments LLC lifted its holdings in Novo Nordisk A/S by 1.4% in the fourth quarter. LRI Investments LLC now owns 13,060 shares of the company's stock worth $1,123,000 after buying an additional 176 shares during the period. Finally, Beacon Financial Group lifted its holdings in Novo Nordisk A/S by 6.5% in the first quarter. Beacon Financial Group now owns 2,884 shares of the company's stock worth $200,000 after buying an additional 177 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NVO stock traded up $0.94 during mid-day trading on Friday, hitting $71.67. The company had a trading volume of 7,345,265 shares, compared to its average volume of 7,144,964. The company has a market capitalization of $320.00 billion, a price-to-earnings ratio of 21.20, a P/E/G ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $139.74. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average price of $70.67 and a 200 day moving average price of $73.80.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVO shares. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.